FAMEFIX™ O

Cefixime is a third-generation oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing the final cross-linking step of peptidoglycan biosynthesis. Unlike first and second-generation cephalosporins, cefixime has enhanced stability against many beta-lactamases and demonstrates superior activity against gram-negative organisms, including H. influenzae, E. coli, Proteus mirabilis, and Klebsiella pneumoniae. Its oral bioavailability of approximately 40–50% allows reliable therapeutic drug levels without parenteral administration.

Ofloxacin is a second-generation fluoroquinolone antibiotic that acts through a completely different and complementary mechanism. It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV — enzymes essential for DNA replication, transcription, repair, and recombination. By trapping the enzyme-DNA complex in a cleaved state, ofloxacin causes lethal double-strand DNA breaks. This dual-target mechanism makes it effective against a broad range of gram-positive and gram-negative organisms and significantly reduces the likelihood of resistance emergence during therapy.

The combination of cefixime and ofloxacin provides synergistic, dual-mechanism bactericidal cover — attacking both cell wall synthesis and DNA replication simultaneously — broadening the spectrum to include atypical organisms such as Chlamydia, Mycoplasma, and Legionella alongside the standard gram-negative pathogens.

FAMEFIX™ O is indicated for moderate-to-severe bacterial infections where dual antimicrobial cover is clinically warranted, particularly in infections with suspected or confirmed mixed gram-negative and atypical organism involvement.

Urinary Tract Infections: Complicated UTIs, pyelonephritis, and urethritis caused by E. coli, Klebsiella, Proteus, and Pseudomonas species where fluoroquinolone sensitivity is confirmed.

Sexually Transmitted Infections: Uncomplicated and complicated gonococcal infections, non-gonococcal urethritis, cervicitis, and pelvic inflammatory disease caused by Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium.

Respiratory Tract Infections: Community-acquired pneumonia with suspected atypical pathogen involvement, acute exacerbations of chronic bronchitis, and sinusitis unresponsive to standard first-line therapy.

Gastrointestinal Infections: Traveller's diarrhoea, Shigellosis, Salmonellosis, and enteric fever — conditions where the ofloxacin component provides rapid mucosal penetration and clearance.

ENT Infections: Chronic suppurative otitis media, complicated sinusitis, and deep-space neck infections where resistant gram-negative organisms are implicated.

Enteric Fever: Typhoid and paratyphoid fever, where the fluoroquinolone component demonstrates excellent intracellular penetration and efficacy.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.